scispace - formally typeset
P

Peter Tontonoz

Researcher at University of California, Los Angeles

Publications -  289
Citations -  53100

Peter Tontonoz is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Liver X receptor & Nuclear receptor. The author has an hindex of 95, co-authored 264 publications receiving 48991 citations. Previous affiliations of Peter Tontonoz include Tohoku University & University of California, San Diego.

Papers
More filters
Journal ArticleDOI

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor.

TL;DR: The results suggest that the physiologic role of PPAR gamma 2 is to regulate development of the adipose lineage in response to endogenous lipid activators and that this factor may serve to link the process of adipocyte differentiation to systemic lipid metabolism.
Journal ArticleDOI

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma.

TL;DR: A pivotal role is suggested for PPARγ and its endogenous ligand in adipocyte development and glucose homeostasis and as a target for intervention in metabolic disorders.
Journal ArticleDOI

mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.

TL;DR: In this paper, an enhancer from the 5'-flanking region of the adipocyte P2 (aP2) gene that directs high-level adipocyte-specific gene expression in both cultured cells and transgenic mice was identified.
Journal ArticleDOI

Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ

TL;DR: The data suggest that the biologic effects of oxLDL are coordinated by two sets of receptors, one on the cell surface, which binds and internalizes the particle, and one in the nucleus, which is transcriptionally activated by its component lipids.
Journal ArticleDOI

Fat and beyond: the diverse biology of PPARgamma.

TL;DR: Recent advances in the understanding of the diverse biological actions of PPARgamma are reviewed with an eye toward the expanding therapeutic potential of PPargamma agonist drugs.